Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi AppTec Files for $1 Billion-Plus IPO in Hong Kong

publication date: Sep 19, 2018

WuXi AppTec has filed for a Hong Kong IPO that is expected to raise at least $1 billion. The company, China's largest CRO/CMO, completed a $354 million IPO on the Shanghai Exchange just over four months ago. Since then, its shares have nearly quadrupled, giving the company a market valuation of $13.1 billion. This is in addition to the $13.4 billion valuation of WuXi Biologics, which IPO'd in Hong Kong one year ago. Three years ago, the company was privatized by its Chairman, Ge Li, plus investors that included Ally Bridge Group and Hillhouse Capital. More details....

Stock Symbol: (SHA: 603259) (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.